Contineum Therapeutics In... (CTNM)
12.91
0.14 (1.10%)
At close: Jan 15, 2025, 12:49 PM
undefined% (undefined)
| Bid | 12.9 |
| Market Cap | 332.79M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.36 |
| PE Ratio (ttm) | -35.86 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 13.2 |
| Volume | 29,476 |
| Avg. Volume (20D) | 97,995 |
| Open | 13.56 |
| Previous Close | 12.77 |
| Day's Range | 12.85 - 13.56 |
| 52-Week Range | 12.33 - 22.00 |
| Beta | undefined |
About CTNM
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). Th...
Industry Biotechnology
Sector Healthcare
IPO Date n/a
Employees 31
Stock Exchange NASDAQ
Ticker Symbol CTNM
Website https://www.contineum-tx.com
Analyst Forecast
According to 4 analyst ratings, the average rating for CTNM stock is "Buy." The 12-month stock price forecast is $30, which is an increase of 132.38% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
